Shattuck Labs Inc
STTK2.280USD
+0.050+2.24%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
109.22MValor de mercado
PerdaP/L TTM
Mais detalhes de Shattuck Labs Inc Empresa
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Informações da empresa
Código da empresaSTTK
Nome da EmpresaShattuck Labs Inc
Data de listagemOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Número de funcionários44
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 09
Endereço500 W. 5Th Street
CidadeAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78701
Telefone15129004690
Sitehttps://www.shattucklabs.com/
Código da empresaSTTK
Data de listagemOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Outro
45.62%
Investidores
Investidores
Proporção
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Outro
45.62%
Tipos de investidores
Investidores
Proporção
Hedge Fund
28.47%
Investment Advisor/Hedge Fund
17.07%
Private Equity
13.16%
Corporation
12.56%
Investment Advisor
8.23%
Family Office
3.74%
Individual Investor
2.44%
Research Firm
1.52%
Outro
12.81%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
2023Q2
215
27.61M
64.91%
-8.42M
2023Q1
223
27.26M
64.10%
-8.88M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Prosight Capital
6.64M
13.86%
--
--
Mar 31, 2025
Redmile Group, LLC
5.54M
11.56%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
4.67M
9.76%
--
--
Mar 31, 2025
Hornblower Capital Holdings, LLC
2.89M
6.04%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
5.45%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.40M
5.01%
-7.92K
-0.33%
Mar 31, 2025
The Clark Estates Inc.
1.48M
3.08%
--
--
Mar 31, 2025
Pinnacle Associates Ltd.
1.30M
2.71%
-25.00K
-1.89%
Mar 31, 2025
683 Capital Management LLC
1.05M
2.19%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
